Work

PARP inhibitors: the race is on

Year: 2016
Type: editorial
Abstract: Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 ( BRCA1/2 ) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition ( Bryant et al, 2005 ; Farmer et al, 2005 ), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific synthetic lethality ( Yap et al., 2011 ; O’Connor, 2015 ). In 2014, olaparib (Lynparza; AstraZeneca, London, UK) was the first PARP inhibitor to be approved by the European Medicines Agency as maintenance therapy for responding patients with BRCA1/2 mutant ovarian cancer following platinum-based chemotherapy, and the first to obtain accelerated approval by the US Food and Drug Administration (FDA) for advanced BRCA1/2 mutant ovarian cancer while confirmatory trials are completed. There are, however, several other potent and bona fide PARP inhibitors, including rucaparib (AGO14699; Clovis, Boulder, CO, USA), niraparib (MK4827; Tesaro, Waltham, MA, USA), talazoparib (BMN-673; Medivation, San Francisco, CA, USA) and veliparib (ABT-888; Abbvie, North Chicago, IL, USA), which are all currently in late phase clinical trial development ( Table 1 ). Rucaparib was granted breakthrough therapy designation by the FDA in April 2015, following the results of the ARIEL2 trial ( Kristeleit et al., 2015 ) for use as monotherapy in patients with BRCA1/2 mutant (germline or somatic) advanced ovarian cancer after at least two prior lines of platinum-containing therapy. Table 1 Table showing the response rates and predominant toxicities for different PARP inhibitors in patients with advanced ovarian cancer Full size table
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W2318905487
Cites: 22
Cited by: 158
Related to: 10